Pharvaris (NASDAQ:PHVS) Hits New 52-Week High – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) reached a new 52-week high during trading on Thursday . The stock traded as high as $34.43 and last traded at $34.0050, with a volume of 7619 shares. The stock had previously closed at $33.29.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PHVS shares. Morgan Stanley upped their price objective on shares of Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $49.64.

Pharvaris Trading Up 2.1%

The business has a fifty day moving average of $30.56 and a 200 day moving average of $27.97. The company has a market capitalization of $2.22 billion, a PE ratio of -10.69 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Equities analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Insider Activity

In other news, Director Robert Glassman sold 10,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the sale, the director directly owned 10,500 shares of the company’s stock, valued at approximately $313,110. This represents a 48.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Anne Lesage sold 21,700 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total value of $656,642.00. Following the sale, the insider directly owned 56,450 shares of the company’s stock, valued at approximately $1,708,177. This represents a 27.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 215,209 shares of company stock worth $6,431,945 over the last ninety days. 11.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP grew its position in Pharvaris by 472.3% during the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after buying an additional 261,355 shares during the period. DV Trading LLC purchased a new stake in Pharvaris during the 1st quarter worth about $4,067,000. Stempoint Capital LP raised its position in shares of Pharvaris by 48.4% in the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after buying an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC lifted its stake in shares of Pharvaris by 23.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after purchasing an additional 20,000 shares during the period. Finally, Amundi lifted its position in Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after buying an additional 3,312 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.